CA2925862A1 - Compounds for affinity chromatography and for extending the half-life of a therapeutic agent - Google Patents
Compounds for affinity chromatography and for extending the half-life of a therapeutic agent Download PDFInfo
- Publication number
- CA2925862A1 CA2925862A1 CA2925862A CA2925862A CA2925862A1 CA 2925862 A1 CA2925862 A1 CA 2925862A1 CA 2925862 A CA2925862 A CA 2925862A CA 2925862 A CA2925862 A CA 2925862A CA 2925862 A1 CA2925862 A1 CA 2925862A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- unsubstituted
- heteroaryl
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885146P | 2013-10-01 | 2013-10-01 | |
| US61/885,146 | 2013-10-01 | ||
| US201462025994P | 2014-07-17 | 2014-07-17 | |
| US62/025,994 | 2014-07-17 | ||
| PCT/IB2014/064998 WO2015049651A1 (en) | 2013-10-01 | 2014-10-01 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2925862A1 true CA2925862A1 (en) | 2015-04-09 |
Family
ID=51743521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2925862A Abandoned CA2925862A1 (en) | 2013-10-01 | 2014-10-01 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9809558B2 (OSRAM) |
| EP (1) | EP3052483B1 (OSRAM) |
| JP (1) | JP2016534984A (OSRAM) |
| KR (1) | KR20160060660A (OSRAM) |
| CN (1) | CN105593222B (OSRAM) |
| AU (1) | AU2014330781B2 (OSRAM) |
| BR (1) | BR112016007371A2 (OSRAM) |
| CA (1) | CA2925862A1 (OSRAM) |
| ES (1) | ES2721098T3 (OSRAM) |
| RU (1) | RU2016117052A (OSRAM) |
| SG (1) | SG11201601870VA (OSRAM) |
| WO (1) | WO2015049651A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170066839A1 (en) | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
| US10697982B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies |
| US10697983B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies |
| US20200047084A1 (en) * | 2017-03-30 | 2020-02-13 | Hitachi Chemical Company, Ltd. | Separation material |
| JP7688395B2 (ja) * | 2018-11-26 | 2025-06-04 | ノース カロライナ ステイト ユニヴァーシティ | 宿主細胞タンパク質の捕捉のためのペプチドリガンド |
| MX2021007444A (es) | 2018-12-21 | 2021-08-05 | Jiangsu Hengrui Medicine Co | Proteina biespecifica. |
| HUE069128T2 (hu) | 2019-12-06 | 2025-02-28 | Vertex Pharma | Szubsztituált tetrahidrofurán vegyületek mint nátriumcsatornák modulátorai |
| AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| WO2022266236A1 (en) | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| US12428427B2 (en) | 2021-12-16 | 2025-09-30 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH187973A4 (de) * | 1973-02-09 | 1977-03-31 | Hoechst Ag | Verfahren zum optischen Aufhellen von Textilmaterialien |
| US4722896A (en) | 1981-01-26 | 1988-02-02 | The Beth Israel Hospital Association | Method for affinity purification of hybridoma antibodies |
| US5849874A (en) | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| JP2825755B2 (ja) * | 1993-04-07 | 1998-11-18 | 大塚製薬株式会社 | ピペリジン誘導体を有効成分とする末梢血管拡張剤および新規ピペリジン誘導体 |
| US5935927A (en) * | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
| GB9914825D0 (en) * | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
| NZ514403A (en) | 1999-12-27 | 2002-10-25 | Japan Tobacco Inc | Fused-ring compounds and use thereof as drugs |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB2403222A (en) | 2002-04-01 | 2004-12-29 | Utah Ventures Ii L P | Tissue-specific endothelial membrane proteins |
| DE60326735D1 (de) | 2002-08-02 | 2009-04-30 | Genesoft Pharmaceuticals Inc | Biaryl-verbindungen mit antiinfektiver wirkung |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| EP2298770A1 (en) | 2005-11-03 | 2011-03-23 | ChemBridge Corporation | Heterocyclic compounds as TrkA modulators |
| LT2459220T (lt) | 2009-07-31 | 2020-12-28 | Ascendis Pharma A/S | Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu |
| JP5744886B2 (ja) * | 2009-10-19 | 2015-07-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロペンタンカルボキサミド誘導体、このような化合物を含む薬物及びそれらの使用 |
| JP2013538798A (ja) * | 2010-08-03 | 2013-10-17 | グラフィニティ ファーマシューティカルズ ゲーエムベーハー | アフィニティクロマトグラフィーによる抗体およびＦｃ融合タンパク質精製のためのリガンド |
| WO2012020080A2 (en) | 2010-08-12 | 2012-02-16 | Graffinity Pharmaceuticals Gmbh | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II |
| US9480751B2 (en) | 2011-04-11 | 2016-11-01 | Yeda Research And Development Co. Ltd. | Albumin binding probes and drug conjugates thereof |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
-
2014
- 2014-10-01 CA CA2925862A patent/CA2925862A1/en not_active Abandoned
- 2014-10-01 AU AU2014330781A patent/AU2014330781B2/en not_active Ceased
- 2014-10-01 BR BR112016007371A patent/BR112016007371A2/pt not_active Application Discontinuation
- 2014-10-01 WO PCT/IB2014/064998 patent/WO2015049651A1/en not_active Ceased
- 2014-10-01 US US15/026,725 patent/US9809558B2/en not_active Expired - Fee Related
- 2014-10-01 JP JP2016519325A patent/JP2016534984A/ja active Pending
- 2014-10-01 EP EP14786355.9A patent/EP3052483B1/en active Active
- 2014-10-01 SG SG11201601870VA patent/SG11201601870VA/en unknown
- 2014-10-01 CN CN201480054551.4A patent/CN105593222B/zh not_active Expired - Fee Related
- 2014-10-01 KR KR1020167008267A patent/KR20160060660A/ko not_active Withdrawn
- 2014-10-01 ES ES14786355T patent/ES2721098T3/es active Active
- 2014-10-01 RU RU2016117052A patent/RU2016117052A/ru not_active Application Discontinuation
-
2017
- 2017-09-07 US US15/698,020 patent/US9938243B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9809558B2 (en) | 2017-11-07 |
| EP3052483A1 (en) | 2016-08-10 |
| AU2014330781A1 (en) | 2016-04-07 |
| CN105593222B (zh) | 2018-02-09 |
| CN105593222A (zh) | 2016-05-18 |
| US9938243B2 (en) | 2018-04-10 |
| US20160221962A1 (en) | 2016-08-04 |
| WO2015049651A1 (en) | 2015-04-09 |
| AU2014330781B2 (en) | 2017-05-04 |
| SG11201601870VA (en) | 2016-04-28 |
| RU2016117052A3 (OSRAM) | 2018-06-27 |
| US20170369448A1 (en) | 2017-12-28 |
| RU2016117052A (ru) | 2017-11-10 |
| BR112016007371A2 (pt) | 2017-08-01 |
| ES2721098T3 (es) | 2019-07-26 |
| JP2016534984A (ja) | 2016-11-10 |
| KR20160060660A (ko) | 2016-05-30 |
| EP3052483B1 (en) | 2019-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3052483B1 (en) | Compounds for affinity chromatography | |
| Hofstee | Hydrophobic affinity chromatography of proteins | |
| JP7387440B2 (ja) | Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド | |
| US10662261B2 (en) | Chelator and use thereof | |
| JP6524272B2 (ja) | 両性イオン性試薬 | |
| JPH10506987A (ja) | クロマトグラフ用樹脂およびその使用方法 | |
| EA011168B1 (ru) | Способ очистки конъюгатов альбумина | |
| PT1874825E (pt) | Ligandos de afinidade | |
| US7335768B2 (en) | Cucurbit [n] uril compounds and analogs, and methods of making and using the same | |
| JP2025513521A (ja) | 治療薬を送達するための環状ペプチド | |
| CN105592860A (zh) | 抗体组合物和用于其的缓冲体系 | |
| WO2012165356A1 (ja) | 感温性ポリアミノ酸またはその塩 | |
| JP4750035B2 (ja) | 光切断型リンカーを利用したリガンド固定化固相担体 | |
| AU2024230594A1 (en) | Photoswitchable compounds and affinity ligands, and their use for the optical control of affinity matrices | |
| CN103923217B (zh) | 6-氨基己酸纤维素酯及其合成方法和应用 | |
| WO2009043899A1 (en) | Drug transfer into living cells | |
| JP2008517033A (ja) | オキシム、チアゾリジン、ジチアン、ジチオランまたはヒドラゾンが連結した成長ホルモンの類似体の作製方法 | |
| US20240024493A1 (en) | Purification methods for large scale synthesis of cucurbit[7]uril-peg conjugates | |
| JP7421554B2 (ja) | 二量体ペプチド－リン脂質コンジュゲートのための最適化された方法 | |
| US8551994B2 (en) | Affinity adsorbents for fibrinogen | |
| JP2019058885A (ja) | 吸着材及び標的物質の精製方法 | |
| CN114933629A (zh) | 一种基于巯基-烯基叠氮偶联反应的多肽或蛋白质定向修饰方法 | |
| GB2637134A (en) | Collagen related peptide | |
| CN106928093A (zh) | 氰基非天然氨基酸的制备及其在生物正交拉曼检测上的应用 | |
| CN116874642A (zh) | 一种金属螯合层析介质及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171010 |
|
| FZDE | Dead |
Effective date: 20200923 |